Spondyloarthritis & psoriatic arthritis
Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One‐Year Double‐Blind, Randomized, Placebo‐Controlled Trial Using High‐Resolution Peripheral Quantitative Computed Tomography
Authors' conclusion
Secukinumab demonstrates a potential benefit in facilitating partial erosion repair and preventing enthesiophyte progression in PsA.
Study context
- Population
- Patients with active psoriatic arthritis (PsA) and ≥1 erosion in metacarpophalangeal joints (MCPJs) 2 to 434 per-protocol
- Participants
- 40 patients
- Comparison
- Subcutaneous secukinumab vs placebo
- Primary endpoint
- Change in erosion volume on MCPJs 2 to 4 measured by high-resolution peripheral quantitative computed tomography (HR-pQCT)
- Follow-up
- 24 and 48 weeks
Methodological detailsphase 4, double-blind, placebo-controlled, 1:1 randomisation, per-protocol analysis
- Phase 4
- Double-blind
- Placebo-controlled
- 1:1 randomisation
- Per-protocol analysis
Primary result
As reported in the abstract
Erosion volume, median change
Secukinumab
−0.1
median · IQR −0.5–0.0
Placebo
0.0
median · IQR −0.2–0.4
P = 0.004
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Enthesiophyte progression (GEE) | 0.264 (0.080–0.878) | P = 0.030 | |
| Partial erosion healing (GEE) | 2.882 (1.130–7.349) | P = 0.027 | |
| 0.050.21520Odds ratio (log scale) |
| Outcome | P value |
|---|---|
| Enthesiophyte volume, median change | P = 0.067 |
Original publication
Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One‐Year Double‐Blind, Randomized, Placebo‐Controlled Trial Using High‐Resolution Peripheral Quantitative Computed Tomography. Arthritis Rheumatol. Published 23 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →